Search - tctmd.com

Displaying 21 - 40 of 50

Sort: Relevancy | Date

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

Radial Access Doubled for Left Main PCI in the UK Between 2007 and 2014

Yael L. Maxwell

September 21, 2018

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

News Conference News TCT 2016

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

Todd Neale

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

News Conference News TCT 2015

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2014

Bendavia to Prevent Mitochondrial Transition Pore Opening

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Amir Lerman, C. Michael Gibson

September 16, 2014

Presentation TCT 2014

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Presenter: Alexandre Abizaid, Elazer R. Edelman, Greg L. Kaluza

September 16, 2014

Presentation TCT 2014

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

Presenter: Alexandre Abizaid, Elazer R. Edelman, Dawn Bardot

September 16, 2014

Advertisement

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

Transitioning to Monotherapy in Patients After PCI

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Radial Access Doubled for Left Main PCI in the UK Between 2007 and 2014

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Cangrelor IV: Transitioning to Oral ADP Antagonists

Keynote: Simplified Trials, Community Engagement Key to Reinvention of Clinical Research

Discussion Highlights Merits, Limitations of Small Trials

Bendavia to Prevent Mitochondrial Transition Pore Opening

Experimental Requirements and Device Validation: Critical Changes Impacting Transition to Human Testing

Translational Research in Transition: Emerging Tools and Methods for Validation of Device Performance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content